Clinical trial
MatErnal BLood IS Source to Accurately Diagnose Fetal Aneuploidy
NCT01122524 · Verinata Health, Inc., Industry · Completed
Key facts
| NCT number | NCT01122524 |
|---|---|
| Title | MatErnal BLood IS Source to Accurately Diagnose Fetal Aneuploidy |
| Official title | A Prospective, Multi-center Observational Study With Blinded, Nested Case:Control Analyses to Evaluate the Performance of the Verinata Health Prenatal Aneuploidy Diagnostic Test |
| Acronym | MELISSA |
| Lead sponsor | Verinata Health, Inc., Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Pregnant Women, Prenatal Care |
| Enrollment | 10,000 |
| Start date | Jun 1, 2010 |
| Primary completion | Sep 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | May 13, 2010 |
| Last update posted | Oct 10, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: